TaiMed Biologics (4147) — Capital Reinvestment Ratio

Latest as of December 2025: 0.65x

TaiMed Biologics (4147) has a Capital Reinvestment Ratio of 0.65x as of December 2025, meaning it reinvests 1% of its operating cash flow (NT$25.95 Million) in capital expenditures (NT$16.75 Million). Check TaiMed Biologics tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.65x
Capex / Operating Cash Flow

Operating Cash Flow

NT$25.95 Million
TWD

Capital Expenditures

NT$16.75 Million
TWD

Data as of

Dec 2025
Most recent filing

TaiMed Biologics Capital Reinvestment Ratio (2025–2025)

This chart tracks TaiMed Biologics's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see 4147 cash flow metrics.

Annual Capital Reinvestment Ratio for TaiMed Biologics (2025–2025)

Year-by-year Capital Reinvestment Ratio for TaiMed Biologics from 2025 to 2025. See cash generation quality of TaiMed Biologics to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (TWD) Capital Expenditures YoY Change
2025 0.12x NT$191.14 Million NT$22.77 Million —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow